Conagen Produces Two Thaumatin Protein Natural Sweeteners at Scale
100,000 times sweeter than table sugar
Bedford, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Food and beverages brands get two more tools for their sugar reduction toolkits as Conagen announced the successful scale-up production of two new high-intensity sweeteners, thaumatin I and thaumatin II. The development will expand commercial partner Sweegen’s robust sugar reduction solutions of zero-sugar natural sweeteners.
Thaumatin is a group of proteins found in the fruits of the tropical plant Thaumatococcus danielli. Each protein, thaumatin I and thaumatin II, varies slightly in sweetness profiles. Both proteins have been evaluated as 100,000 times sweeter than sugar on a molar basis and 3,000 times sweeter on a weight basis. The high sweetness factor can translate into a strategic cost-effective sugar reduction solution for brands seeking to get the most out of a natural sweetener.
The thaumatin proteins were developed from Conagen’s peptide production platform, which had previously been used for the scaled production of another peptide sweetener, brazzein. “Conagen constantly improves its protein and peptide production platforms to generate more exciting new products," said Casey Lippmeier, vice president of innovation at Conagen. "In this case, the platform has been leveraged to make thaumatin by several innovative approaches, but under a significantly shorter R&D timeline.”
These two new, high-purity thaumatin proteins add to Sweegen’s creative portfolio of sugar reduction solutions to help brands make low-calorie products. Brands can now explore the synergistic benefits of formulations that contain thaumatin and other products from Sweegen’s Signature Sweetener portfolio, including brazzein and stevia. This diversity of natural, high-intensity sweeteners represents the most cost-effective approach for reducing sugar in food and beverages to deliver the best tasting match for the sweetness of sugar.
The desire for natural sweeteners will drive the demand for fruit and plant-based sweeteners, such as thaumatin and stevia, respectively. The main advantages to sweetening food and beverages with thaumatin are its familiarity and acceptance by consumers and the fact that it is approved for use in products by the majority of the countries in the world.
Health-conscious consumers are generally more accepting of natural sweeteners than sugar and artificial sweeteners. According to FMCG Gurus, Top 10 Future Trends 2030, "60% of global consumers currently believe natural sweeteners are healthier alternatives to sugar." The trend report further stated, "Increasingly, consumers will want only products that contain real and authentic ingredients, and sweeteners will be no exception to the rule. As such, this will drive demand for sweeteners sourced directly from fruits and plants, something that the industry will respond to."
Like most other proteins, when thaumatin proteins are consumed, they are digested into amino acids. However, because thaumatin communicates such a strong sweet taste, the levels used in most applications contribute almost no calories. It is one of the most intense sweeteners ever discovered.
Consumers increasingly expect to stock their pantries with low-to-no sugar products with food and beverages that fit into their lifestyle and diets. Thaumatin can complement a number of consumer lifestyles, such as diabetic, ketogenic, or low-to-no carbohydrate diets. These sweet proteins are low on the glycemic index.
“Thaumatin is the second announced product generated from our peptide platform, which fits well into our existing world-scale, precision fermentation infrastructure.” Lippmeier further added, “Peptides and small proteins like brazzein and thaumatin can be very difficult to make economically; however, now that we have successfully scaled multiple peptides and proteins, we are willing to collaborate with other customers to make other novel peptide products.”
Regulatory approval for thaumatin as natural sweeteners has passed in the European Union (E957), Israel, and Japan. In the United States, it is generally recognized as safe as a flavoring agent (FEMA GRAS 3732).
Conagen is a product-focused, synthetic biology R&D company with large-scale manufacturing service capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mandatory Notification of Trade16.5.2022 11:18:48 CEST | Press release
Please refer to the attached form of notification of transaction by primary insiders under the DNO ASA Employee Synthetic Share Program. This notification has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3. Attachment Form of Notification Settlement of Synthetic Shares Nicholas Whiteley
Game studio Omnigame picks Agillic to scale personalisation and international growth16.5.2022 10:30:00 CEST | Press release
Press release, Copenhagen, 16 May 2022 OmnigameApS is an independent Danish online game studio on an ambitious mission to deliver quality, highly entertaining games and boost player engagement through its new communication strategy. Uncompromising on quality in both their games and customer experience, Omnigame turned to Agillic for operational efficiency, empowering its team to turn its copious data into highly personalised and relevant communication, and to scale the business internationally without ballooning headcounts. With implementation by Agillic Gold Solution Partner NexusOne, Omnigame was up and running on Agillic in less than three months. Since April, it has been leveraging the platform to run automated customer journeys, using content, personalisation and language versions dynamically across three owned channels - with room to scale. Omnigame’s Head of CX, Pia Nørland, says: ‘We are really excited to have started with Agillic. With the first flows already in place and runn
Stockwik förvärvar Cordinator Medical Service16.5.2022 10:00:00 CEST | Pressemelding
Solna den 16 maj 2022 PRESSMEDDELANDE Stockwik Förvaltning AB (publ) har ingått avtal om förvärv av Cordinator Medical Service AB (”Cordinator”). Stockwik förvärvar samtliga aktier i Cordinator. Som ett av Östergötlands ledande företag inom sitt verksamhetsområde företagshälsovård och privat sjukvård kompletterar Cordinator på ett utmärkt sätt Stockwiks övriga företag inom segmentet; TEAM Hälsa, Hela Företagshälsovård, Tjugonde Friskvård och Hälsobolaget. Med Cordinators verksamhet i Linköping och Norrköping täcker vi nu en stor del av Sverige. På Cordinators kliniker finns idag ca 30 anställda och konsulter. Verksamheten har bedrivits av Gunilla Rundqvist sedan 2004 med fokus på kvalitet och kundnöjdhet. För den senaste tolvmånadersperioden, per den 30 april 2022, uppgick Cordinators nettoomsättning till 26 MSEK. EBITDA-resultatet uppgick för motsvarande period till knappa 4 MSEK. Transaktionen sker på skuldfri basis till en EBITDA-multipel 6x. BAKGRUND OCH MOTIV Förvärvet av Cordinat
Grayscale Investments® Launches First European ETF: Grayscale Future of Finance UCITS ETF16.5.2022 09:00:00 CEST | Press release
Grayscale Future of Finance UCITS ETF (ticker: GFOF) listed on select exchanges across Europe Grayscale’s first European ETF accelerates its global strategic expansion NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Grayscale Investments®, the world’s largest digital currency asset manager, today announced its first European ETF, Grayscale Future of Finance UCITS ETF (ticker: GFOF), will list on the London Stock Exchange (LSE), Borsa Italiana, and Deutsche Börse Xetra. GFOF UCITS ETF will also be passported for sale across Europe. GFOF UCITS ETF tracks the investment performance of the Bloomberg Grayscale Future of Finance Index and seeks to offer investors exposure to companies at the intersection of finance, technology, and digital assets – companies that are building the digital economy – all through the familiar ETF wrapper. In February 2022, Grayscale listed an ETF in the United States that tracks the investment performance of the Bloomberg Grayscale Future of Finance Index. The Bloomb
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme16.5.2022 08:45:00 CEST | Press release
Company Announcement No. 33/2022 Copenhagen, 16 May 2022 Transactions in connection with share buy-back programme On 9 March 2022, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 700 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2023. The following transactions have been executed from 9 May to 12 May 2022: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement737,564104,827,453 9 May 202222,530147.253,317,65110 May 202220,250151.163,061,06311 May 2